BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call shows a mixed picture: a 25% revenue increase and improved net loss are positive, but the inherent regulatory and product development risks pose concerns. The absence of strategic initiatives and shareholder return discussions limits the positive impact. Cash reserves have decreased, but cost controls are in place. The lack of market cap data prevents assessment of stock sensitivity. Overall, the sentiments are balanced, leading to a neutral prediction for stock movement.
Key Financial Performance
Revenue BioCardia reported revenue of $2.5 million for Q1 2026, representing a 25% increase year-over-year. This growth was attributed to higher sales of its CardiAMP cell therapy system.
Net Loss The company reported a net loss of $3.2 million for Q1 2026, which is a 10% improvement compared to the same period last year. The improvement was due to cost-cutting measures and operational efficiencies.
Research and Development Expenses R&D expenses were $1.8 million for Q1 2026, a 5% increase year-over-year. This was driven by ongoing clinical trials and product development efforts.
General and Administrative Expenses G&A expenses were $1.2 million for Q1 2026, remaining flat compared to the previous year, as the company maintained strict cost controls.
Cash and Cash Equivalents The company ended Q1 2026 with $8.5 million in cash and cash equivalents, a decrease from $10 million at the end of Q1 2025. The decline was due to increased investment in R&D and operational activities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approvals: The company faces inherent uncertainties in obtaining regulatory approvals for new products and technologies, which could impact their operational results and future performance.
Product Development: Developing new products and technologies carries inherent risks that may affect the company's ability to meet its strategic objectives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Benvenuti Investor
BioCardia Financial
BioCardia Form
CEO President
Conference Instructions
Director McClung
EDT Ladies
Executive CEO
Financial Results
Instructions Participants
Ladies gentleman
McClung Chief
Officer PM
PM EDT
Peto BioCardia
President Director
Relations Executive
Relations Forward
Results Update
SEC content
Update Conference
afternoon BioCardia
end Peto
factor statement
gentleman afternoon
BCDA Transcript
BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript
Unknown5-15
The earnings call shows a mixed picture: a 25% revenue increase and improved net loss are positive, but the inherent regulatory and product development risks pose concerns. The absence of strategic initiatives and shareholder return discussions limits the positive impact. Cash reserves have decreased, but cost controls are in place. The lack of market cap data prevents assessment of stock sensitivity. Overall, the sentiments are balanced, leading to a neutral prediction for stock movement.
BioCardia, Inc. (BCDA) Q4 2025 Earnings Call Transcript
Unknown3-24
The earnings call reveals mixed sentiments: increased R&D expenses and operational costs are concerning, but the CardiAMP HF's potential FDA approval and competitive advantage offer optimism. The Q&A highlights slow trial enrollment and non-significant p-values, but also potential regulatory success and partnership interest. The absence of strong financial guidance and the challenge of rising costs balance the positive aspects, leading to a neutral outlook for the stock price over the next two weeks.
BioCardia, Inc. (BCDA) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call shows mixed signals: a slight increase in revenue, reduced SG&A expenses, and a decrease in net loss for Q3, but an increase in net loss over nine months. The Q&A reveals positive progress in trials but lacks transparency in patient enrollment numbers. The strategic plan highlights potential partnerships and regulatory approvals, which could be positive. However, the absence of market cap data and the lack of immediate strong catalysts lead to a neutral outlook for short-term stock movement.
BioCardia, Inc. (BCDA) Q2 2025 Earnings Call Transcript
Unknown8-11
The earnings call reveals mixed signals. Financial performance shows increased net loss and cash usage, which are negative. However, there are ongoing advancements in trials and partnerships, which are positive. The Q&A highlights uncertainties around regulatory approvals and partnerships, but also potential growth opportunities. The neutral sentiment reflects this balance of positive developments against financial challenges and uncertainties.
BCDA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
